Invizyne Technologies, Inc.
Publicly observedMonrovia, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Monrovia | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Invizyne Technologies, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | UCL9ZV4PLW23 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jul 2026Publicly observed
NIH SBIR/STTR award: SimplePath IIB: Pre-clinical development of Cannabinoid analogs
USD 1,034,289.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant1 Apr 2025Publicly observed
NIH SBIR/STTR award: Bio-Click: A cell-free high-throughput platform for the engineering of enzymatic group transfer reactions
USD 283,805.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.